EXTON, Pa., May 6, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, at six months following launch of Xtandi (Astellas Pharma/Medivation's enzalutamide), surveyed urologists and medical oncologists prescribed Xtandi to a respective 19 percent and 24 percent of their metastatic castrate-resistant prostate cancer (mCRPC) patients who have failed to respond or had very rapid progression from docetaxel (Sanofi's Taxotere, generics) treatment. In six months' time, surveyed respondents expect to prescribe Xtandi to 35-39 percent of these mCRPC patients, making Xtandi the patient share leader in this patient population.
The second wave of the LaunchTrends®: Xtandi report series, fielded six months following the launch of Xtandi in the United States, finds that 30 percent of surveyed urologists have prescribed Xtandi in clinical practice compared with 43 percent of surveyed medical oncologists. In contrast, data published just one month post launch of Xtandi revealed that less than 10 percent surveyed urologists had prescribed Xtandi in clinical practice (i.e., outside of clinical trials), compared with 39 percent of their medical oncologist counterparts. Lack of familiarity with Xtandi and because many eligible patients are already receiving Zytiga (Johnson & Johnson/Janssen Biotech/Janssen Cilag's abiraterone) are key reasons cited by surveyed respondents for not having prescribed Xtandi yet. However, the majority of current non-prescribing urologists (61 percent) and medical oncologists (88 percent) surveyed tell us that they expect to prescribe Xtandi within the next six months.
The findings also reveal that if Xtandi successfully secures a first-line label extension for use in chemotherapy-naive, asymptomatic or minimally symptomatic mCRPC, surveyed medical oncologists and urologists would prescribe it to nearly half of their eligible patients. Surveyed respondents' estimates of Xtandi's patient share in this patient population exceeds their current estimates of patient share for any other currently prescribed therapy in this setting, including Zytiga, exemplifying surveyed physicians' enthusiasm for this agent and eagerness to use it earlier in the mCRPC treatment algorithm.
"Xtandi is experiencing rapid uptake within its FDA-approved indication for docetaxel-pretreated mCRPC, and its inclusion on National Comprehensive Cancer Network guidelines for use in chemotherapy-naive, asymptomatic mCRPC patients who are not candidates for docetaxel is spurring its use in this earlier disease setting," said Decision Resources Group Senior Director of Oncology Rachel Webster , D.Phil. "While more than half of surveyed physicians report decreased use of Jevtana (Sanofi's cabazitaxel) in their docetaxel pretreated mCRPC patients, more than half of surveyed respondents currently report no change in their use of Zytiga in this setting."
About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
For more information, contact:
Decision Resources Group
|SOURCE BioTrends Research Group|
Copyright©2012 PR Newswire.
All rights reserved